NEW YORK, Dec. 6, 2017 /PRNewswire/ -- In keeping with the commitment to dynamically provide members with timely information, WallStEquities.com has issued free tailored Stock Review on PLX, XXII, CRMD, and IBIO which is a click away at www.wallstequities.com/registration. Featured on WallStEquities.com is the Biotechnology space, which consists of companies engaged in the R&D of new drugs, medical devices, and procedures. The industry includes the manufacturing and marketing of drugs as a result of direct research and development. Equities in this morning's lineup are: Protalix BioTherapeutics Inc. (NYSE MKT: PLX), 22nd Century Group Inc. (NYSE MKT: XXII), CorMedix Inc. (NYSE MKT: CRMD), and iBio Inc. (NYSE MKT: IBIO). Wall St. Equities explores the latest technical developments on today's equity selection at:
Shares in Karmiel, Israel-based Protalix BioTherapeutics Inc. saw a correction of 1.44%, ending Tuesday's trading session at $0.67. The stock recorded a trading volume of 566,621 shares. The Company's shares have gained 16.96% over the last three months and 50.61% on an YTD basis. The stock is trading 1.48% below its 50-day moving average. Moreover, shares of Protalix BioTherapeutics, which focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally, have a Relative Strength Index (RSI) of 45.91.
On November 29th, 2017, Protalix BioTherapeutics announced the completion of enrollment in its phase II clinical trial evaluating OPRX-106, the Company's oral antiTNF product candidate, in patients with ulcerative colitis. It is the Company's proprietary plant cell-expressed recombinant human tumor necrosis factor receptor II fused to an IgG1 Fc domain. The Company expects to report top-line results from this study in Q1 2018. Complimentary subscription to our free research report on PLX at:
22nd Century Group
Clarence, New York headquartered 22nd Century Group Inc.'s stock rose 3.03%, closing the day at $2.38 with a total trading volume of 1.34 million shares. The Company's shares have advanced 19.60% in the past month, 7.21% in the previous three months, and 118.35% since the start of this year. The stock is trading 28.25% above its 200-day moving average. Additionally, shares of 22nd Century, which provides technology that allows for the level of nicotine and other nicotinic alkaloids in tobacco plants to be decreased or increased through genetic engineering and plant breeding, have an RSI of 47.84.
On December 04th, 2017, 22nd Century announced the hiring of Juan Sanchez Tamburrino, Ph.D. as the Company's Vice President of R&D. Dr. Tamburrino was previously the head of the Plant Biotechnology Division of British American Tobacco. Access the free research report on XXII now by signing up at:
On Tuesday, shares in Bridgewater, New Jersey-based CorMedix Inc. recorded a trading volume of 1.49 million shares, which was higher than their three months average volume of 1.37 million shares. The stock ended the day 2.27% lower at $0.62. The Company's shares have advanced 38.36% in the previous three months, and are trading above their 50-day moving average by 8.24%. Furthermore, shares of CorMedix have an RSI of 57.63.
On November 20th, 2017, CorMedix announced a common stock transaction of 624,246 shares at a per share purchase price of $0.48 to members of the Company's Board of Directors, the executive management team, and certain employees, as previously announced in association with the recent preferred stock and backstop financing from a long-term institutional investor. Gross proceeds from the offering are expected to be approximately $300,000, which will apply against the Backstop Agreement and reduce the total warrants issuable to the investor by 6%. Are you already registered with Wall St. Equities? Do so now for free, and get the report on CRMD at:
New York-based iBio Inc.'s stock climbed 2.47%, finishing yesterday's session at $0.17. A total volume of 1.03 million shares was traded, which was above their three months average volume of 741,900 shares. The Company's shares are trading below their 50-day moving average by 41.10%. Additionally, shares of iBio have an RSI of 17.82.
On November 30th, 2017, iBio announced the closing of its previously announced public offering of 22,500,000 shares of its common stock at a price to the public of $0.20 per common share. Gross proceeds to iBio from this offering are approximately $4,500,000 before deducting underwriting discounts and commissions and other offering expenses payable by the Company. Aspiring Member, please take a moment to register below for your free research report on IBIO at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Wall St. Equities